Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC slashes target price for Hilton Food Group

(Sharecast News) - RBC Capital Markets has slashed its target price for Hilton Food Group by nearly 30% after cutting its medium-term targets following the food packaging company's mixed first-half results. The broker trimmed its target price from 1,050p to 750p and kept a 'sector perform' rating on the stock.

HFG's share price plunged 17% on Wednesday after the company reported that softness in its seafood division - driven by "significant" raw material inflation - weighed on figures for the six months to 29 June, with statutory profit before tax (PBT) down 4.7% year-on-year.

As a result, RBC said it has cut its EBIT forecasts for HFG over the next three years. For 2025, its adjusted PBT now sits at just £73m, below company guidance of £77m-81m.

"Additionally, we think elevated seafood prices will limit both the pace of volume recovery and premiumisation - especially considering the currently depressed consumer backdrop," RBC said.

Looking ahead, the broker was somewhat upbeat, expecting HFP's volume growth to turn positive in 2027. It highlighted the company's international expansion, but said that higher investments in both capacity and working capital could limit earnings growth.

Using RBC's new estimates, the stock trades at an 2026 EV/NOPAT valuation multiple of 8x, which it sees as a "fair" discount to sector peers Cranswick (17x) and Premier Foods (12x).

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.